This company has been acquired
NGM Stock Overview
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
NGM Biopharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.54 |
| 52 Week High | US$4.69 |
| 52 Week Low | US$0.60 |
| Beta | 1.27 |
| 1 Month Change | 1.32% |
| 3 Month Change | 14.93% |
| 1 Year Change | -59.79% |
| 3 Year Change | -93.94% |
| 5 Year Change | -90.41% |
| Change since IPO | -89.52% |
Recent News & Updates
Recent updates
What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You
Dec 19
We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate
Oct 05Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates
Aug 09Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky
Jun 27NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't
Apr 17We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully
Dec 20NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails
Oct 17NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President
Jun 30NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022
Jun 21Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Jun 15Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week
May 09NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad
Apr 26Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Feb 21We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely
Nov 08Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Jul 09NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Mar 06Shareholder Returns
| NGM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.1% | -0.3% | 0.7% |
| 1Y | -59.8% | 0.4% | 8.1% |
Return vs Industry: NGM underperformed the US Pharmaceuticals industry which returned 15.5% over the past year.
Return vs Market: NGM underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| NGM volatility | |
|---|---|
| NGM Average Weekly Movement | 10.3% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: NGM's share price has been volatile over the past 3 months.
Volatility Over Time: NGM's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 138 | David Woodhouse | www.ngmbio.com |
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy.
NGM Biopharmaceuticals, Inc. Fundamentals Summary
| NGM fundamental statistics | |
|---|---|
| Market cap | US$128.53m |
| Earnings (TTM) | -US$142.37m |
| Revenue (TTM) | US$4.42m |
29.1x
P/S Ratio-0.9x
P/E RatioIs NGM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NGM income statement (TTM) | |
|---|---|
| Revenue | US$4.42m |
| Cost of Revenue | US$114.23m |
| Gross Profit | -US$109.81m |
| Other Expenses | US$32.56m |
| Earnings | -US$142.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.71 |
| Gross Margin | -2,486.12% |
| Net Profit Margin | -3,223.34% |
| Debt/Equity Ratio | 0% |
How did NGM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/04/05 12:42 |
| End of Day Share Price | 2024/04/05 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NGM Biopharmaceuticals, Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Luchini | BMO Capital Markets Equity Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Paul Choi | Goldman Sachs |